Tag: Acalabrutinib

First approved by the FDA in 2017 for mantle cell lymphoma, **calquence** (acalabrutinib) is a targeted oral medication used to treat certain B-cell malignancies. It is not a traditional chemotherapy drug but a Bruton's tyrosine kinase (BTK) inhibitor, a class of targeted therapies that work by interrupting specific signaling pathways within cancer cells. This targeted approach aims to limit the negative effects on healthy cells, offering a more precise treatment method.

BTK inhibitors have revolutionized the treatment landscape for many B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), by providing a highly effective alternative to traditional chemotherapy. The core principle behind these targeted therapies is understanding **what is the mechanism of action of BTK inhibitors** and how they disrupt the specific pathways that fuel cancer growth.